


Amendment to the Claims


The claimed invention is:

1. (Currently Amended) A compound of formula (Ia), (Ib), or (Ic):



or a pharmaceutically acceptable salt, ~~prodrug~~, tautomer, hydrate or ~~solvate~~ thereof, wherein:

R<sup>1</sup> is a group of the formula



wherein R<sup>1</sup> can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, hydroxy, oxo, mercapto, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>5</sub>-C<sub>10</sub>)aryl or (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)aryloxy or (C<sub>5</sub>-C<sub>10</sub>)heteroaryloxy, (C<sub>5</sub>-C<sub>10</sub>)ar(C<sub>1</sub>-C<sub>6</sub>)alkyl or (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkyl,

(C<sub>5</sub>-C<sub>10</sub>)ar(C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl- and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, cyano, nitro, carbamoyl, (C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylaminocarbonyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylaminocarbonyl, (C<sub>5</sub>-C<sub>10</sub>)arylcabonyl, (C<sub>5</sub>-C<sub>10</sub>)aryloxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, and (C<sub>5</sub>-C<sub>10</sub>)arylsulfonyl;

each R<sup>3</sup> is independently selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, (C<sub>1</sub>-C<sub>6</sub>)alkyl HN-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-NH-, amino(C=O)-, aminoO<sub>2</sub>S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, HO-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, H<sub>2</sub>N(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(C=O)-, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)- and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, alkoxy, phenoxy, amino of R<sup>3</sup> is optionally substituted by at least one substituent independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo, H<sub>2</sub>N-, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, and (C<sub>1</sub>-C<sub>6</sub>)alkylHN-;

s is an integer from one to five;

and

R<sup>6</sup> is selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, phenyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(SO<sub>2</sub>)-, phenyl-(SO<sub>2</sub>)-, H<sub>2</sub>N-(SO<sub>2</sub>)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(SO<sub>2</sub>)-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>N-(SO<sub>2</sub>)-, phenyl-NH-(SO<sub>2</sub>)-, (phenyl)<sub>2</sub>N-(SO<sub>2</sub>)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-(C=O)-, H<sub>2</sub>N-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(C=O)-, phenyl-NH-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>N-(C=O)-, (phenyl)<sub>2</sub>N-(C=O)-, phenyl-[(C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-(C=O)-,

and (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N)-(C=O)-;

where alkyl, alkenyl, alkynyl, phenyl, benzyl, cycloalkyl, alkoxy, phenoxy, amino of R<sup>6</sup> is optionally substituted with at least one moiety independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl,

(C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, phenyl, benzyl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, formyl, NC-,

(C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, phenyl-(C=O)-,

(C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-, HO-(C=O)-,

(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-(C=O)-,

(C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(C=O)-,

(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)-, phenyl-NH-(C=O)-,

(C<sub>5</sub>-C<sub>10</sub>)heterocyclic-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-,

((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>-N-(C=O)-, phenyl-(((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N)-(C=O)-, hydroxy,

(C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, phenoxy,

(C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-,

(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-O-, phenyl-(C=O)-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-O-,

(C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-O-, O<sub>2</sub>N-, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino,

((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>-amino, formamidyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-,

(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-NH-, phenyl-(C=O)-NH-,

(C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-NH-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-NH-,

(C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-[(((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-(C=O)-[(C<sub>1</sub>-C<sub>6</sub>)alkyl-N]-,

(C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>NH-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-SO<sub>2</sub>NH-, phenyl-SO<sub>2</sub>NH-,

(C<sub>5</sub>-C<sub>10</sub>)heterocyclic-SO<sub>2</sub>NH- and (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-SO<sub>2</sub>NH-;

wherein the phenyl moiety of a R<sup>6</sup> substituent is optionally further substituted with at least one radical independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkyl and perfluoro(C<sub>1</sub>-C<sub>6</sub>)alkoxy.

2. (Previously Cancelled)

3. (Previously Cancelled)

4. (Previously Cancelled)

5. (Previously Cancelled)

6. (Previously Cancelled)

7. (Previously Cancelled)
8. (Previously Cancelled)
9. (Original) A compound of claim 1, wherein s is one to two; R<sup>3</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and R<sup>6</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl.
10. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
11. (Cancelled)
12. (Cancelled)
13. (Previously Presented) A compound 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof.
14. (Previously Presented) A pharmaceutical composition comprising 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.